Immune Checkpoint Pathway Expression in Lymphocyte Subpopulations in Patients with Common Variable Immunodeficiency

Paulina Mertowska1, Sebastian Mertowski1, Konrad Smolak1

  • 1Department of Experimental Immunology, Medical University of Lublin, 20-093 Lublin, Poland.

Cancers
|November 14, 2023
PubMed

Insights

This study reveals significant immune checkpoint molecule alterations in chronic lymphocytic leukemia (CLL) and common variable immunodeficiency (CVID) patients. These findings offer insights for improved diagnostics and personalized therapies for these immune and blood disorders.

Area of Science:

  • Immunology
  • Hematology
  • Oncology

Background:

  • Chronic lymphocytic leukemia (CLL) and common variable immunodeficiency (CVID) are distinct conditions involving immune system dysregulation.
  • Immune checkpoint pathways play crucial roles in immune homeostasis and are implicated in various diseases.

Purpose of the Study:

  • To investigate immune checkpoint molecule expression (PD-1/PD-L1, CTLA-4/CD86, CD200R/CD200) on lymphocyte subpopulations in CLL and CVID.
  • To compare these expression levels with healthy controls and between the two disease groups.

Main Methods:

  • Flow cytometry was used to analyze the percentage of immune checkpoint molecules and their ligands on peripheral blood lymphocyte subpopulations.
  • Enzyme immunoassay tests were conducted to determine the serum concentrations of these soluble molecules.

Main Results:

  • Significant alterations in the percentage of tested immune checkpoint molecules were observed on T and B lymphocyte subpopulations in both CLL and CVID patients compared to healthy volunteers.
  • Expression differences were also noted between CLL and CVID patient groups.
  • Serum concentrations of soluble immune checkpoint molecules corroborated the flow cytometry findings.

Conclusions:

  • The study highlights significant immune checkpoint pathway dysregulation in CLL and CVID.
  • These findings may contribute to developing novel diagnostic and therapeutic strategies for these conditions.
  • Understanding these pathways can aid in monitoring immune status and improving patient care for immunodeficiencies and hematological malignancies.